Autolus Therapeutics to further expand operations at the CGT Catapult manufacturing centre to enable commercial manufacture of CAR-T cell therapies

Autolus Therapeutics are further expanding their operations at the Cell and Gene Therapy Catapult (CGT Catapult) manufacturing centre, and are collaborating with CGT Catapult to achieve licensure for the commercial manufacture of their CAR-T cell therapies. This collaboration facilitates the company’s plans to manufacture CAR-T cell therapies for both clinical and commercial supply and the CGT Catapult and associated UK supply chain will gain new capability and expertise, adding to the favourable cell and gene therapy ecosystem in the UK.

Autolus are a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. They are one of five collaborators to have established their large-scale manufacturing operations at the CGT Catapult manufacturing centre in Stevenage, UK.

The facility, which has recently doubled in capacity, provides infrastructure, expertise and a surrounding cell and gene therapy ecosystem which is favourable for the growth of companies moving towards clinical adoption. Autolus are expanding within the facility to utilise additional cleanroom space in the newly operational modules, supporting the manufacture of materials for their pipeline products.

Matthew Durdy, CEO, Cell and Gene Therapy Catapult commented:
“We are proud to undertake this collaboration with Autolus, a pioneering company that has been showing tremendous progress with their pipeline products for oncology. We look forward to working with Autolus to meet all of the standards required for commercial CAR-T cell therapy manufacturing.

With its unique operating model, the Manufacturing Centre is well suited as an international base for manufacturing innovation at scale and, having recently expanded, has the capacity to support new and existing collaborating companies as they grow.”


About the Cell and Gene Therapy Catapult
The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 230 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or visit http://www.gov.uk/innovate-uk.

The CGT Catapult manufacturing centre has been backed by over £75m of funding, including investment from the UK government’s Industrial Strategy Challenge Fund, the Department for Business Energy and Industrial Strategy, Innovate UK and from the European Regional Development Fund. As part of this funding, £3.36m from the European Regional Development Fund and £12m from the Medicines Manufacturing Industrial Strategy Challenge Fund were invested to support the expansion phase of construction at the CGT Catapult manufacturing centre.

FTI Consulting for CGT Catapult:
Michael Trace +44 (0) 203 319 5674 / michael.trace@fticonsulting.com
George Kendrick +44 (0) 203 727 1411/ george.kendrick@fticonsulting.com

More within